title: Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib: is it under-reported and does it have any clinical significance?
authors.forename: Derville
authors.initials: D
authors.lastname: O'Shea
authors.forename: Gerard
authors.initials: G
authors.lastname: Crotty
authors.forename: Peig
authors.initials: P
authors.lastname: Carroll
authors.forename: Eibhlin
authors.initials: E
authors.lastname: Conneally
authors.forename: Shaun
authors.initials: S
authors.lastname: McCann
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Neat
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002869:Chromosome Aberrations; D002999:Clone Cells; D006801:Humans; D000068877:Imatinib Mesylate; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate